Embecta Corp. (NASDAQ:EMBC) Announces $0.01 Quarterly Dividend

Embecta Corp. (NASDAQ:EMBC) declared a quarterly dividend on Friday, August 7th. Investors of record on Thursday, August 27th will be given a dividend of 0.01 per share on Tuesday, September 15th. This represents a c) dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 27th.

Embecta has a dividend payout ratio of 1.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.

Embecta Trading Up 26.3%

NASDAQ EMBC traded up $0.92 on Friday, hitting $4.42. 5,586,683 shares of the company were exchanged, compared to its average volume of 1,573,631. The firm has a 50 day moving average of $3.32 and a two-hundred day moving average of $6.67. The company has a market cap of $262.24 million, a P/E ratio of 2.33 and a beta of 0.81. Embecta has a 1-year low of $2.77 and a 1-year high of $15.55.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29. Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. During the same quarter last year, the company posted $1.12 EPS. The company’s quarterly revenue was down 8.1% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Research analysts anticipate that Embecta will post 1.62 EPS for the current fiscal year.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.